12.02.21 Endpoints News: Samsung Biologics takes on manufacturing duties for GreenLight’s Covid-19 vaccine Share: Share on Linkedin Share on Twitter Share on Facebook GreenLight Biosciences’ deal with Samsung is featured in Endpoints News for its deal with Samsung to manufacture mRNA Covid-19 vaccine at a commercial scale GreenLight CEO Andrey Zarur is quoted as saying “There is an urgent need to develop vaccines for the whole world.” An extract from the article is below. The company was founded in 2008 to use its mRNA technology to protect both humans and agriculture, including honeybees and crops. It was virtually unknown before the merger. Now, the company is looking to set up a blueprint for vaccinating the world from Covid-19, and hopes to do so through improved mRNA manufacturing capabilities. It’s been working on seasonal flu and sickle cell disease vaccines as well, but it got its start while trying to shake up the pesticides market for industrial agriculture. “There is an urgent need to develop vaccines for the whole world,” GreenLight CEO Andrey Zarur said in a press release. “Our vaccine trial will open the way to make vaccines that are available to everybody, not just citizens of developed countries.” There are currently three plants at the Samsung Songdo campus. A fourth is on the way, and the CDMO just got approved to build a fifth in November. Read the full article here.